Exploring the Abundance of Biomarkers in Lung Cancer: Current Applications and Future Prospects for Precision Medicine

Get up to date on the latest clinical data guiding optimal use of biomarkers in the care of your patients with advanced NSCLC with this educational program featuring an interactive on-demand webcast and downloadable slidesets from a live CCO webinar.

Share

Program Content

No activities added yet

Activities

Molecular Testing/Immunotherapy
Molecular Testing Overview and Biomarkers Predicting Response to Immune-Based Therapies in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 28, 2021

Expires: June 27, 2022

<i>EGFR</i>, <i>EGFR</i> ex20ins, <i>HER2</i>
Predictive Biomarkers for Targeted Therapies in Advanced NSCLC: EGFR mutations, EGFR Exon 20 Insertions, and HER2 Mutations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 28, 2021

Expires: June 27, 2022

<i>ALK, ROS1, RET, NTRK, KRAS</i> G12C, <i>MET</i>ex14
Predictive Biomarkers for Targeted Therapies in Advanced NSCLC: ALK and ROS1 Rearrangements, RET and NTRK Fusions, and KRAS G12C and METex14 Mutations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 28, 2021

Expires: June 27, 2022

<i>EP</i>: NSCLC Biomarkers 2021
ExpressPoints
Exploring the Abundance of Biomarkers in Lung Cancer: Current Applications and Future Prospects for Precision Medicine
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 08, 2021

Expires: July 07, 2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Turning Point Therapeutics Inc